ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
21.303,16
0,21%
S&P 500
6.086,37
0,61%
Dow Jones
44.156,73
0,30%
Euro vs US Dollar
1,03985
-0,09%
Bitcoin
101.423,76
-2,13%
Pepperstone
Advertisement
Registration Strip Icon for discussion Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. Vereinigtes Königreich
  5. LSE
  6. Addex Therapeutics Ltd (0QNV)

  7. Addex Therapeutics Ltd (0QNV) News

0QNV

Addex Therapeutics (0QNV)

Addex Therapeutics Ltd
Von:
Sortieren nach:
 Showing the most relevant articles for your search:LSE:0QNV
DatumZeitQuelleÜberschriftSymbolFirma
08/01/202507h00UK RegulatoryAddex to Present at the 2025 Swiss Equities Baader ConferenceLSE:0QNVAddex Therapeutics Ltd
22/11/202407h00UK RegulatoryAddex Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateLSE:0QNVAddex Therapeutics Ltd
11/11/202407h00UK RegulatoryAddex Provisional 2024 Third Quarter Results Showed Net Loss Compared to Second Quarter 2024LSE:0QNVAddex Therapeutics Ltd
30/09/202407h00UK RegulatoryAddex Therapeutics Reports 2024 Half Year and Second Quarter Financial Results and Provides Corporate UpdateLSE:0QNVAddex Therapeutics Ltd
19/09/202407h00UK RegulatoryAddex Provisional 2024 Half-Year and Second Quarter Result increased from a Net loss to a Net ProfitLSE:0QNVAddex Therapeutics Ltd
04/09/202407h00UK RegulatoryAddex to Participate in the H.C. Wainwright 26th Annual Global Investment ConferenceLSE:0QNVAddex Therapeutics Ltd
27/08/202407h00UK RegulatoryAddex and Indivior Select Clinical Candidates from GABAB Positive Allosteric Modulator Research CollaborationLSE:0QNVAddex Therapeutics Ltd
22/07/202407h00UK RegulatoryAddex’s Partner Discontinues ADX71149 development in EpilepsyLSE:0QNVAddex Therapeutics Ltd
15/07/202407h00UK RegulatoryAddex Presents Positive Results from GABAB PAM Cough Program at the Thirteenth London International Cough Symposium (13th LICS)LSE:0QNVAddex Therapeutics Ltd
12/07/202407h00UK RegulatoryAddex To Present at the Thirteenth London International Cough Symposium (13th LICS)LSE:0QNVAddex Therapeutics Ltd
01/07/202407h00UK RegulatoryAddex Shareholders Approve All Resolutions at Annual General MeetingLSE:0QNVAddex Therapeutics Ltd
06/06/202407h00UK RegulatoryAddex Therapeutics Reports Q1 2024 Financial Results and Provides Corporate UpdateLSE:0QNVAddex Therapeutics Ltd
05/06/202407h00UK RegulatoryAddex Convenes Annual General Meeting 2024LSE:0QNVAddex Therapeutics Ltd
31/05/202407h00UK RegulatoryAddex Therapeutics to Release Q1 2024 Financial Results and Host Conference Call on June 6, 2024LSE:0QNVAddex Therapeutics Ltd
08/05/202407h00UK RegulatoryAddex to Present at Bio€quity Europe 2024LSE:0QNVAddex Therapeutics Ltd
29/04/202407h00UK RegulatoryAddex Provides Update on ADX71149 Phase 2 Epilepsy StudyLSE:0QNVAddex Therapeutics Ltd
19/04/202407h00UK RegulatoryAddex to Present at the Swiss Biotech Day 2024LSE:0QNVAddex Therapeutics Ltd
18/04/202407h00UK RegulatoryAddex Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate UpdateLSE:0QNVAddex Therapeutics Ltd
11/04/202407h00UK RegulatoryAddex Therapeutics to Release Full-Year 2023 Financial Results and Host Conference Call on April 18, 2024LSE:0QNVAddex Therapeutics Ltd
03/04/202407h00UK RegulatoryAddex and Perceptive Launch Neurosterix with $63 Million to Accelerate Development of Allosteric Modulator Therapeutics for Neurological DisordersLSE:0QNVAddex Therapeutics Ltd
14/03/202407h00UK RegulatoryAddex to Present at the Bio-Europe Spring 2024 ConferenceLSE:0QNVAddex Therapeutics Ltd
31/01/202407h00UK RegulatoryAddex Enters into At-The-Market ADS Offering Agreement with H.C. Wainwright & Co. LLC.LSE:0QNVAddex Therapeutics Ltd
 Showing the most relevant articles for your search:LSE:0QNV

Kürzlich von Ihnen besucht

COIN
BTCUSD
Bitcoin
DBI
MDAX
MDAX
NYSE
MCD
McDonalds
TG
ALV
Allianz
FX
EURUSD
Euro vs US Dollar
NASDAQ
NVDA
NVIDIA
TG
DTE
Deutsche Telekom
USOTC
RHHBY
Roche (QX)
TG
D7G
Nel ASA
COIN
DOGEUSD
Dogecoin
NYSE
NKE
Nike
COIN
ETHUSD
Ethereum
NASDAQ
TSLA
Tesla
USOTC
BNPQY
BNP Paribas (QX)
FX
EURJPY
Euro vs Yen
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2025 ADVFN PLC - Alle Rechte vorbehalten